LA PrEP Impact and Cost-effectiveness (TEAMS)
Epidemiological Impact and Cost-effectiveness of Long-acting Antiretrovirals for Pre-exposure Prophylaxis Among Key Populations in Thailand
Institute of HIV Research and Innovation Foundation, Thailand
10,720 participants
Mar 15, 2022
INTERVENTIONAL
Conditions
Summary
This study will have three components: 1. Discrete choice experiments 2. Analysis of routine service data 3. Impact and cost-effectiveness analyses using results from 1 and 2
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In-depth interviews (IDI) 20 MSM,20 TGW, current, previous PrEP users will assess which attributes are relevant each population. Posters will be used to recruit for IDIs. Self-reported HIV-negative who either report interest in current or past PrEP use will be eligible to participate in IDI. IDI will be conducted by a study by in-person, on-line interviews.
Focus group discussion (FGD) will discuss a interested information from IDIs. IDIs will be informed, invited to a FGD. FGD recruit 6-10 IDI. 10 random number will be generated using statistical if more 10 individuals show interest in participating in a FGD. If there are less than 6 accepted participants for a FGD, the backup list or new participant will be invited. Study will perform FGD by in-person, on-line conference. Data obtained during a process will be used to create a list of attributes for each population, their levels to include in the choice tasks, ensuring that a choices are plausible, exchangeable.
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05774548